Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. more
Time Frame | CVM | Sector | S&P500 |
---|---|---|---|
1-Week Return | 38% | -2.27% | -0.57% |
1-Month Return | 9.51% | -3.96% | 1.21% |
3-Month Return | -46.09% | -9.7% | 7.57% |
6-Month Return | -46.51% | -3.37% | 11.45% |
1-Year Return | -75.27% | 3.71% | 28.48% |
3-Year Return | -91.98% | 3.8% | 29.52% |
5-Year Return | -91.09% | 39.78% | 90.66% |
10-Year Return | -95% | 106.91% | 203.75% |
Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 462.75K | 558.66K | - | - | - | [{"date":"2019-09-30","value":82.83,"profit":true},{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Cost of Revenue | 12.66K | 17.84K | 499.00K | 3.88M | 3.96M | [{"date":"2019-09-30","value":0.32,"profit":true},{"date":"2020-09-30","value":0.45,"profit":true},{"date":"2021-09-30","value":12.61,"profit":true},{"date":"2022-09-30","value":98.11,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Gross Profit | 450.10K | 540.82K | (499.00K) | (3.88M) | (3.96M) | [{"date":"2019-09-30","value":83.22,"profit":true},{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":-92.27,"profit":false},{"date":"2022-09-30","value":-718.05,"profit":false},{"date":"2023-09-30","value":-731.91,"profit":false}] |
Gross Margin | 97.26% | 96.81% | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-09-30","value":100,"profit":true},{"date":"2020-09-30","value":99.53,"profit":true},{"date":"2021-09-30","value":null,"profit":false},{"date":"2022-09-30","value":null,"profit":false},{"date":"2023-09-30","value":null,"profit":false}] |
Operating Expenses | 20.20M | 28.99M | 36.19M | 36.06M | 31.48M | [{"date":"2019-09-30","value":55.8,"profit":true},{"date":"2020-09-30","value":80.08,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":99.64,"profit":true},{"date":"2023-09-30","value":86.96,"profit":true}] |
Operating Income | (20.20M) | (28.99M) | (36.19M) | (36.06M) | (31.48M) | [{"date":"2019-09-30","value":-2019510600,"profit":false},{"date":"2020-09-30","value":-2898505500,"profit":false},{"date":"2021-09-30","value":-3619412900,"profit":false},{"date":"2022-09-30","value":-3606279300,"profit":false},{"date":"2023-09-30","value":-3147607400,"profit":false}] |
Total Non-Operating Income/Expense | (3.74M) | (2.31M) | (1.32M) | (1.72M) | (1.39M) | [{"date":"2019-09-30","value":-373701500,"profit":false},{"date":"2020-09-30","value":-231191400,"profit":false},{"date":"2021-09-30","value":-131626800,"profit":false},{"date":"2022-09-30","value":-171892200,"profit":false},{"date":"2023-09-30","value":-139364400,"profit":false}] |
Pre-Tax Income | (22.13M) | (30.26M) | (36.36M) | (36.70M) | (32.19M) | [{"date":"2019-09-30","value":-2213464000,"profit":false},{"date":"2020-09-30","value":-3025524400,"profit":false},{"date":"2021-09-30","value":-3636110900,"profit":false},{"date":"2022-09-30","value":-3670068100,"profit":false},{"date":"2023-09-30","value":-3219430200,"profit":false}] |
Income Taxes | 2.56M | 1.97M | 2.83M | 1.57M | 632.60K | [{"date":"2019-09-30","value":90.51,"profit":true},{"date":"2020-09-30","value":69.63,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":55.44,"profit":true},{"date":"2023-09-30","value":22.38,"profit":true}] |
Income After Taxes | (24.69M) | (32.22M) | (39.19M) | (38.27M) | (32.83M) | [{"date":"2019-09-30","value":-2469272400,"profit":false},{"date":"2020-09-30","value":-3222333600,"profit":false},{"date":"2021-09-30","value":-3918756300,"profit":false},{"date":"2022-09-30","value":-3826769100,"profit":false},{"date":"2023-09-30","value":-3282690500,"profit":false}] |
Income From Continuous Operations | (22.21M) | (30.26M) | (36.36M) | (36.70M) | (32.19M) | [{"date":"2019-09-30","value":-2220766200,"profit":false},{"date":"2020-09-30","value":-3025524400,"profit":false},{"date":"2021-09-30","value":-3636110900,"profit":false},{"date":"2022-09-30","value":-3670068100,"profit":false},{"date":"2023-09-30","value":-3219430300,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (24.69M) | (32.22M) | (39.19M) | (38.27M) | (32.37M) | [{"date":"2019-09-30","value":-2469272400,"profit":false},{"date":"2020-09-30","value":-3222333600,"profit":false},{"date":"2021-09-30","value":-3918756300,"profit":false},{"date":"2022-09-30","value":-3826769100,"profit":false},{"date":"2023-09-30","value":-3236585500,"profit":false}] |
EPS (Diluted) | (0.68) | (0.80) | (0.90) | (0.87) | (0.72) | [{"date":"2019-09-30","value":-68,"profit":false},{"date":"2020-09-30","value":-80,"profit":false},{"date":"2021-09-30","value":-90,"profit":false},{"date":"2022-09-30","value":-87,"profit":false},{"date":"2023-09-30","value":-72,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CVM | |
---|---|
Cash Ratio | 0.07 |
Current Ratio | 0.64 |
Quick Ratio | 0.18 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CVM | |
---|---|
ROA (LTM) | -61.41% |
ROE (LTM) | -250.20% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CVM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.65 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.35 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CVM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 11797.42 |
P/B | 5.55 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
CEL-SCI Corp (CVM) share price today is $0.69
Yes, Indians can buy shares of CEL-SCI Corp (CVM) on Vested. To buy CEL-SCI Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CVM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of CEL-SCI Corp (CVM) via the Vested app. You can start investing in CEL-SCI Corp (CVM) with a minimum investment of $1.
You can invest in shares of CEL-SCI Corp (CVM) via Vested in three simple steps:
The 52-week high price of CEL-SCI Corp (CVM) is $3.23. The 52-week low price of CEL-SCI Corp (CVM) is $0.49.
The price-to-earnings (P/E) ratio of CEL-SCI Corp (CVM) is
The price-to-book (P/B) ratio of CEL-SCI Corp (CVM) is 5.55
The dividend yield of CEL-SCI Corp (CVM) is 0.00%
The market capitalization of CEL-SCI Corp (CVM) is $44.71M
The stock symbol (or ticker) of CEL-SCI Corp is CVM